Jens Kuhle

sNfL as a prognostic biomarker of MS at an individual level 0:59
sNfL as a prognostic biomarker of MS at an individual level
Jens Kuhle • 26 Jun 2022
The potential of sNfL as an exploratory endpoint for MS trials 1:03
The potential of sNfL as an exploratory endpoint for MS trials
Jens Kuhle • 26 Jun 2022
Prognostic biomarkers in multiple sclerosis 2:14
Prognostic biomarkers in multiple sclerosis
Jens Kuhle • 26 Jun 2022
Prognostic value of baseline sNfL on treatment effect of evobrutinib 1:23
Prognostic value of baseline sNfL on treatment effect of evobrutinib
Jens Kuhle • 26 Jun 2022
Developing a normative database to improve sNfL performance in MS 5:04
Developing a normative database to improve sNfL performance in MS
Jens Kuhle • 21 Oct 2021
Assessing the interaction between blood NfL levels and BTK inhibitor efficacy in MS 1:08
Assessing the interaction between blood NfL levels and BTK inhibitor efficacy in MS
Jens Kuhle • 21 Oct 2021
sNfL identifies patients at higher risk of future disease activity beyond NEDA-3 status 2:18
sNfL identifies patients at higher risk of future disease activity beyond NEDA-3 status
Jens Kuhle • 21 Oct 2021
How do we move sNfL into clinical practice? 1:31
How do we move sNfL into clinical practice?
Jens Kuhle • 21 Oct 2021
Serum NfL: a first-in-class biomarker paving the way towards precision medicine in MS 2:29
Serum NfL: a first-in-class biomarker paving the way towards precision medicine in MS
Jens Kuhle • 21 Oct 2021
The content of VJNeurology is intended for healthcare professionals